What is Acino Holding AG Shares Outstanding (EOP)?
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Acino Holding AG's shares outstanding for the quarter that ended in Dec. 2013 was 3.5 Mil.
Acino Holding AG's quarterly shares outstanding
increased
from Dec. 2012 (3.4 Mil) to Dec. 2013 (3.5 Mil).
It means Acino Holding AGissued new shares from Dec. 2012 to Dec. 2013 .
Acino Holding AG's annual shares outstanding
increased
from Dec. 2012 (3.4 Mil) to Dec. 2013 (3.5 Mil).
It means Acino Holding AGissued new shares from Dec. 2012 to Dec. 2013 .
Acino Holding AG Shares Outstanding (EOP) Historical Data
The historical data trend for Acino Holding AG's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acino Holding AG's Shares Outstanding (EOP)
For the Drug Manufacturers - General subindustry, Acino Holding AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's Shares Outstanding (EOP) falls into.
Acino Holding AG Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Acino Holding AG (FRA:S3H) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Acino Holding AG Shares Outstanding (EOP) Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:S3H has been successfully added to your 